Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

BLU-667 Shows Promise for Advanced Solid Tumors With RET Alterations

April 15th 2018

BLU-667, a next-generation tyrosine kinase inhibitor, appeared to be well-tolerated and had broad clinical benefit among patients with advanced, RET-altered solid tumors who progressed on prior therapies.

Fresh Focus on Second Primary Cancers

April 5th 2018

When investigators looked at roughly 150,000 cases of well-differentiated thyroid cancer using the SEER database of the National Cancer Institute, they knew that the use of radioactive iodine in conjunction with surgery and other treatments for thyroid cancer had increased dramatically over the years.

Dr. Bouvet Discusses Risk Factors for Thyroid Cancer

April 3rd 2018

Michael Bouvet, MD, professor of surgery, University of California, San Diego, discusses risk factors for thyroid cancer.

Nivolumab Active in Advanced Nasopharyngeal Carcinoma

March 30th 2018

Nivolumab induced an overall response rate of 20.5% in patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).

Dr. Weiss Discusses the Impact of Immunotherapy on Head and Neck Cancer

March 30th 2018

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the impact of immunotherapy in head and neck cancer.

Larotrectinib FDA Submission Completed for TRK Fusion Cancer

March 26th 2018

A rolling new drug application has been completed for larotrectinib (LOXO-101) for the treatment of adult and pediatric patients with locally advanced or metastatic solid tumors harboring an NTRK gene fusion.

Dr. Mell on Individualizing Treatment for Head and Neck Cancer

March 23rd 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses individualizing treatments for patients with head and neck cancer.

Dr. Sacco on Ongoing Trials for Chemoradiation in Head and Neck Cancer

March 21st 2018

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses ongoing trials investigating chemoradiation for patients with head and neck cancer.

No Benefit With Postoperative Chemoradiotherapy Versus RT Alone in HNSCC

March 19th 2018

The addition of weekly carboplatin following surgery and radiation therapy did not improve freedom from locoregional relapse in patients with high-risk cutaneous head and neck squamous cell carcinoma.

Dr. Lopes on Immunotherapy in Head and Neck Cancer

March 15th 2018

Gilberto Lopes Jr, MD, a medical director for International Programs at Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, discusses the role of immunotherapy for patients with head and neck cancer.

FDA Halts Combo Trial of Axalimogene Filolisbac Plus Durvalumab

March 14th 2018

The FDA has put a clinical hold on a phase I/II study of axalimogene filolisbac plus durvalumab (Imfinzi) for the treatment of patients with cervical cancer or head and neck cancer.

Dr. Gold on Defining Head and Neck Squamous Cell Carcinoma

March 10th 2018

Kathryn A. Gold, MD, medical oncologist, associate professor of medicine, UC San Diego Heath, differentiates carcinogen-induced and virally associated head and neck squamous cell carcinoma.

Dr. Mell Discusses Flaws in Risk Stratification for Head and Neck Cancer

February 26th 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses flaws in the current model of risk stratification for patients with head and neck cancer.

Larotrectinib Update Shows Durable Responses in TRK-positive Cancers

February 22nd 2018

Larotrectinib (LOXO-101) induced durable responses in patients with TRK fusion–positive solid tumors, according to updated results for the novel pan-TRK inhibitor.

Dr. Bauml on HPV Vaccination for Head and Neck Cancer

February 22nd 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses HPV vaccination for patients with HPV-related head and neck cancer.

Dr. Califano Discusses the Role of Surgery in Head and Neck Cancer

January 25th 2018

Joseph A. Califano, MD, professor of surgery, University of California, San Diego, discusses the role of surgery in head and neck cancer.

Moving Forward in Head and Neck Squamous Cell Cancer

January 25th 2018

Development of effective therapies for metastatic head and neck cancer has been challenging, and progress has been slow.

Dr. Sacco Discusses Multidisciplinary Care in Head and Neck Cancer

January 18th 2018

Assuntina G. Sacco, MD, assistant professor of medicine, medical oncologist, UC San Diego Health, discusses the importance of multidisciplinary care in the treatment of patients with head and neck cancer.

Dr. Bauml Discusses Biomarkers in Head and Neck Cancer

January 11th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses biomarker development for patients with head and neck cancer.

Dr. Mell on Factors of Risk Stratification in Head and Neck Cancer

January 5th 2018

Loren K. Mell, MD, assistant professor, Department of Radiation Medicine and Applied Sciences, University of California, San Diego School of Medicine, discusses factors that contribute to risk stratification and treatment of head and neck cancer.